CLEC12A and acute myeloid leukemia: Validating our hypothesis, we show in PDX models of pediatric AML, resembling intratumoral heterogeneity of the primary disease, that mono-targeting by CAR-T-cells against CD33, CD38 or CD371 results in rapid antigen escape and disease progression.